The US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) from Sandoz, a Novartis (VTX: NOVN) division, for proposed biosimilar adalimumab to the reference medicine Humira, the company disclosed on Tuesday.
Adalimumab is indicated as a treatment for numerous inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis.
In the US, rheumatoid arthritis affects around 1.5 million people. Every year there are approximately 200,00 new cases diagnosed, with women disproportionately affected by the disease.
The company's submission to the FDA included analytical, preclinical and clinical data. It is expected to demonstrate Sandoz's proposed biosimilar matches the reference biologic in terms of safety, efficacy and quality.
Included in the submission is a pharmacokinetic study involving healthy volunteers and a Phase III confirmatory safety and efficacy study in patients with moderate-to-severe chronic plaque-type psoriasis.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT